Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AVANT: Aclidinium/Formoterol in COPD
NCT03022097Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2017
- Primary completion
- Apr 2022
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of aclidinium bromide + formoterol fumarate in chronic obstructive pulmonary disease (COPD), sponsored by AstraZeneca. Started Feb 2017; status: completed.
02
Drugs
aclidinium bromide + formoterol fumarate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT03022097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03022097.